Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHFS

Nuwellis (CHFS) Stock Price, News & Analysis

Nuwellis logo

About Nuwellis Stock (NASDAQ:CHFS)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.76
$0.82
50-Day Range
$3.53
$6.02
52-Week Range
$4.86
$37.50
Volume
51,878 shs
Average Volume
467,323 shs
Market Capitalization
$4.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Remove Ads
Receive CHFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

CHFS Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Why Is Nuwellis (NUWE) Stock Down Today?
BetterHelp Online Therapy Review 2023
See More Headlines

CHFS Stock Analysis - Frequently Asked Questions

Nuwellis, Inc. (NASDAQ:CHFS) posted its earnings results on Monday, March, 1st. The company reported ($1.57) earnings per share for the quarter, topping analysts' consensus estimates of ($1.91) by $0.34. The company earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%.

Shares of Nuwellis reverse split before market open on Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Biocept (BIOC), VBI Vaccines (VBIV), Immutep (IMMP), NightHawk Biosciences (NHWK) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
3/01/2021
Today
4/08/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:CHFS
Previous Symbol
NASDAQ:SSH
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,110,000.00
Net Margins
-254.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.51 million
Price / Cash Flow
N/A
Book Value
$12.79 per share
Price / Book
0.06

Miscellaneous

Free Float
N/A
Market Cap
$4.57 million
Optionable
Not Optionable
Beta
1.55
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:CHFS) was last updated on 4/9/2025 by MarketBeat.com Staff
From Our Partners